Dare Bioscience, Inc. quarterly report, Q2 FY2022

Business context and reporting period

Daré Bioscience, Inc. is a women’s-health biopharmaceutical company whose operations are principally research and development. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2022. XACIATO, its FDA-approved bacterial-vaginosis treatment, was licensed to Organon; its U.S. commercial launch was expected in Q4 2022. The pipeline includes Ovaprene and Sildenafil Cream, 3.6%, in advanced clinical development, alongside earlier-stage programs.

Key financial metrics

MetricQ2 2022 / June 30, 2022Comparison
Revenue$10.0 million, entirely XACIATO license revenueNone in Q2 2021
Net income (loss)Q2 income $0.414 million; six-month loss $7.985 millionQ2 2021 loss $9.163 million; six-month 2021 loss $16.486 million
Operating expensesQ2 $9.616 million; six-month $18.016 millionQ2 up 5%; six-month up 7% year over year
Research and developmentQ2 $6.798 million; six-month $12.603 millionDown 7% and 4%, respectively, year over year
General and administrativeQ2 $2.793 million; six-month $5.363 millionUp 55% and 43%, respectively, year over year
Cash and cash equivalents$32.071 million$51.674 million at December 31, 2021
Operating cash flowSix-month use of $20.792 millionSix-month 2021 use of $20.168 million
Working capital / total liabilitiesApproximately $33.6 million / $18.361 millionWorking capital as reported by the company

No conventional borrowings were reported at June 30; liabilities include lease obligations. Gross margin was not separately presented. The $10.0 million XACIATO payment was recorded as revenue and receivable at quarter-end and collected in July. Cash flow included a $10.0 million increase in accounts receivable. The $8.751 million deferred grant balance represents funding restricted to DARE-LARC1 development.

Changes versus prior comparable period

Q2 revenue and reported profit reflect the one-time $10.0 million Organon license payment, rather than recurring product sales. Despite the quarterly profit, the company recorded a six-month operating loss of $8.016 million. Six-month net loss improved from 2021, principally reflecting lower operating loss; 2021 also included a $0.370 million gain from forgiveness of a Paycheck Protection Program loan. G&A rose notably with professional services, commercial readiness, insurance, and personnel costs. R&D fell modestly as XACIATO Phase 3 costs ended, partly offset by spending on Ovaprene and Sildenafil Cream.

Financing proceeds from common-stock issuance fell to $1.339 million in the first half of 2022 from $24.626 million in 2021. Shares outstanding rose to 84.821 million at June 30, from 83.944 million at year-end. Stockholder approval in July increased authorized common shares from 120 million to 240 million.

Outlook, commentary and risks

  • Funding and going concern: Management reported substantial doubt about the company’s ability to continue as a going concern and said cash on hand was insufficient for working capital and liquidity needs over the next 12 months from issuance of the statements. It expects continuing operating losses and negative operating cash flows and needs substantial additional capital. Equity financing may dilute shareholders; capital may not be available on acceptable terms.
  • Subsequent funding: After quarter-end, the company collected $10.0 million from Organon and approximately $7.96 million under the Gates Foundation DARE-LARC1 grant. The filing reports approximately $19.41 million received under that grant by the report date. Grant funds are restricted to eligible program costs; the filing does not say these receipts remove the stated going-concern uncertainty.
  • Commercialization: Organon has exclusive worldwide XACIATO rights. Daré may receive $2.5 million following first U.S. commercial sale, up to $180 million in additional milestones, and tiered double-digit royalties. Organon may terminate after the first anniversary on 120 days’ notice. U.S. availability was expected in Q4 2022.
  • Development outlook: The company expected 2022 G&A to increase approximately 25% and R&D approximately 45% versus 2021, subject to available cash. The Ovaprene FDA IDE process was expected to continue into Q3 2022, with an investigator meeting targeted for Q4, subject to FDA approval. Sildenafil Cream’s interim analysis was expected in the second half of 2022; topline data timing would be updated afterward. Topline data from DARE-HRT1 and DARE-VVA1 studies were anticipated in Q4 2022. These are forward-looking targets, not assurances.
  • Key risks and contingencies: Clinical or regulatory setbacks, trial enrollment and timing, manufacturing and third-party performance, commercial acceptance and reimbursement, competition, and the need for further financing could materially affect results. COVID-19 had contributed to slower enrollment and development delays, though the company reported no material adverse effect on the business as a whole to date. The company disclosed no material pending legal proceeding and no material change to previously reported risk factors.

Investor verification points

  1. Confirm Organon launch timing, first commercial sale, milestone eligibility, royalties, and any subsequent commercial performance.
  2. Assess actual cash burn, the impact of post-quarter receipts, the restricted nature and timing of grant funding, and financing needs relative to the going-concern warning.
  3. Track Ovaprene FDA interactions and Phase 3 start, as well as Sildenafil Cream interim-analysis timing and results.
  4. Monitor ATM equity issuance, dilution, available authorized shares, and outstanding options and warrants.
  5. Review whether actual 2022 spending and pipeline progress match management’s expense and development outlook.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.